GILD - Gilead Sciences, Inc.
| 前收市價 | 77.09 |
| 開市 | 76.52 |
| 買盤 | 76.50 x 800 |
| 賣出價 | 76.53 x 800 |
| 今日波幅 | 76.01 - 76.87 |
| 52 週波幅 | 57.17 - 89.74 |
| 成交量 | |
| 平均成交量 | 5,380,456 |
| 市值 | 95.46B |
| Beta 值 (5 年，每月) | 0.40 |
| 市盈率 (最近 12 個月) | 17.31 |
| 每股盈利 (最近 12 個月) | 4.42 |
| 業績公佈日 | 2023年7月31日 - 2023年8月04日 |
| 遠期股息及收益率 | 3.00 (3.89%) |
| 除息日 | 2023年6月14日 |
| 1 年預測目標價 | 91.38 |
Insider Monkey14 Best Biotech Stocks To Buy According To Hedge Funds
In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]
Insider Monkey14 Best Healthcare Dividend Stocks to Buy
In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]
InvestorPlace3 Analyst Upgrades That Smart Investors Won’t Ignore
Even the most experienced investors have only so many hours in the day to perform their due diligence. That’s where analyst ratings can be helpful. Analyst upgrades and downgrades frequently move stocks. Analysts spend a great deal of time covering a particular stock or an entire sector. This gives them access to information and company insiders that retail investors don’t have. One of an analyst’s key responsibilities is to issue a rating and/or price target for the stocks that they cover. Many
Insider Monkey15 Biggest Immunotherapy Companies in the World
In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]
Insider Monkey10 Best Stocks To Buy For A Stock Market Game
In this article, we will be taking a look at the 10 best stocks to buy for a stock market game. To see more of these stocks, you can go directly to see the 5 Best Stocks To Buy For A Stock Market Game. Investing in Penny Stocks In a time when the markets are […]
BenzingaGilead vs. CDC: The $1B Showdown Over HIV Drug Profits
Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help prevent the disease. It generated sales of $147 million in 2022 compared to $371 million a year ago. The FDA approved Gilead's Truvada for HIV prevention in 2012 and its related drug Descovy for the same purpose in 2019. Descovy sales came in at 1.87 billion versus $1.7 billion in 2021. The government i
Insider Monkey27 Largest Biotech Companies in the US
In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in […]
BenzingaWhy Gilead Sciences Stock Is Falling Today
Gilead Sciences Inc (NASDAQ: GILD) reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury (remdesivir) sales, partially offset by increased sales in HIV and Oncology. "Biktarvy outperformed once again, and Oncology revenue increased 59% year-over-year, driven by Trodelvy and Cell Therapy," said Daniel O'Day, Gilead's Chairman & CEO. Product sales decreased by 3% to $6.3 billion; excluding Veklury, product sales increased 15%
- infocast
吉利德首財季盈利遜預期 維持全年預測
美國生物製藥廠吉利德科學(Gilead Sciences)公布,首財季盈利錄得10.1億美元;每股經調整盈利1.37美元,預期為1.54美元;收入為64億美元,預期為63.1億美元。吉利德表示,期內整體開支增加6%,影響業績表現。該集團維持今年每股盈利預測區間不變,仍然是6.6-7美元。 (BC)#吉利德科學 #Gilead Sciences #美股
- AASTOCKS
《美股業績》吉利德科學(GILD.US)季績遜預期 瑞德西韋銷售跌63%
美國藥廠吉利德科學(Gilead Sciences)(GILD.US)公布季績。季度純利10.1億美元，去年因就研發減值27億美元，去年同期純利為1,900萬美元。每股季度攤薄純利80美仙，經調整後為1.37美元，低於市場預期的1.54美元。季度派息每股75美仙。季度收入按年跌3.6%至63.52億美元。 新冠藥物瑞德西韋季度銷售按年跌63%至5.73億美元，市場預期為6.98億美元。愛滋病治療銷售按年升13%至41.9億美元。 吉利德科學股價在延長交易時段升0.5%，報84美元。(fc/da)~ 阿思達克財經新聞 網址: www.aastocks.com
InvestorPlace3 Cash-Rich Biotech Stocks to Bet on for the Long Haul
The Federal Reserve’s recent interest rate hikes mean banks charge much higher interest rates for loans. The interest on loans can be considered the price of borrowing more money. And since acquiring cash now costs more money, it’s becoming much more complicated for companies to invest. For biotech stocks, the pain is clearly borne by investors, who choose to dive into these capital-intensive businesses. For a cash-strapped company, the rising cost of money can be a death sentence. But cash-rich
Insider Monkey12 Best Pharma Dividend Stocks To Buy in 2023
In this article, we discuss 12 best pharma dividend stocks to buy in 2023. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2023. The pharmaceutical industry in the US is one of the largest in […]
InvestorPlaceStrong Quant Screens Say These 7 Growth Stocks Are a Buy
Strong quantitative screens will show investors a variety of growth stocks to buy. For example, StockRover is a screening service that scores stocks on three key metrics. One, growth scores are based on five year historical growth, compared to forward EBITDA estimates. Two, quality scores depend on profitability and a healthy balance sheet. Three, value scores are based on the usual price-to-earnings multiple and earnings per share predictability. Quant scores offer investors a numerical charact
Insider Monkey12 Best Covid Treatment Stocks to Buy Today
In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there’s one thing that can be said for sure, it’s that the coronavirus pandemic has changed the world. The deadly disease, […]
BenzingaGilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients
Kite, a Gilead Science Inc (NASDAQ: GILD) company, announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. Historical SOC is a
BenzingaGilead Exercises First License Option Under Agreement With Nurix Therapeutics
Gilead Sciences Inc (NASDAQ: GILD) has exercised its option to license Nurix Therapeutics Inc's (NASDAQ: NRIX) investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration. GS-6791 is a potent, selective, oral IRAK4 degrader with potential applications in rheumatoid arthritis (RA) and other inflammatory diseases. Under the terms of the Collaboration, Nurix will
Insider MonkeyHere’s Why Gilead Sciences (GILD) Outperformed in Q4
Ariel Investments, an investment management company, released its “Ariel Global Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the Ariel Global Composite delivered a 10.72% gross of fees compared to a +9.76% return for the primary MSCI ACWI Index and a +14.21% gain for the MSCI ACWI […]
Insider MonkeyWhat Contributed to Gilead Sciences (GILD)’s Outperformance in Q4?
ClearBridge Investments, an investment management company, released its “ClearBridge Sustainability Leaders Strategy” fourth 2022 investor letter. A copy of the same can be downloaded here. The strategy underperformed its benchmark, the Russell 3000 Index, in the fourth quarter. In the quarter, the strategy gained in eight of the ten sectors it invested in on an absolute […]
Insider MonkeyTop 10 Drug Companies in USA and Their China Reliance
In this article, we will be taking a look at the top 10 drug companies in USA and their China reliance. To skip our detailed analysis of the pharmaceutical sector, you can go directly to see the Top 5 Drug Companies in USA and Their China Reliance. The US has long been reliant on China […]
InvestorPlace7 Cash-Rich Companies to Invest in During Economic Uncertainty
While it’s generally good to be optimistic, in the market, it also pays to be realistic, thus incentivizing consideration for cash-rich stocks to buy. Here, we’re not necessarily talking about the most exciting ventures available. Rather, we’re targeting enterprises that have plenty of green-colored paper in the bank. This way, these cash-imbued entities can weather whatever storms might break out. At the same time, it doesn’t make too much sense to have plenty of cash if you’re also waist-deep
BenzingaGilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment
Gilead Sciences Inc (NASDAQ: GILD) announced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment. The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations. Related: WHO Recommends Gilead's COVID-19 Therapy For Seve
Insider Monkey25 Most Profitable NASDAQ Stocks Today
In this article, we will look at the 25 most profitable NASDAQ stocks today. If you want to explore similar stocks, you can also take a look at 10 Most Profitable NASDAQ Stocks Today. 2022 was one of the worst years for the NASDAQ, primarily because it is dominated by tech, and tech stocks crashed as […]
Insider MonkeyBillionaire Ken Griffin’s Top 10 High Dividend Stock Picks
In this article, we discuss billionaire Ken Griffin’s top 10 high-dividend stock picks. You can skip our detailed analysis of Ken Griffin’s investment strategy, and go directly to read Billionaire Ken Griffin’s Top 5 High Dividend Stock Picks. Ken Griffin’s Citadel Investment Group is one of the 15 Biggest Hedge Funds in the World by […]
BenzingaKite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings
Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with a consistent safety profile observed since the two-year analysis. In the Phase 2 treated patient cohort (n=55
Insider MonkeyGilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript February 2, 2023 Operator: Good afternoon. Thank you for attending today’s Fourth Quarter and Full Year 2022 Gilead Sciences Earnings Conference Call. My name is Henna, and I will be your moderator for today’s call. I would now like to pass the conference over to our […]